LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
Revenue
LAVA Therapeutics NV
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Revenue
$6.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
AEX:PHARM
|
Revenue
$245.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
43%
|
|
Uniqure NV
NASDAQ:QURE
|
Revenue
$15.8m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
argenx SE
XBRU:ARGX
|
Revenue
$1.2B
|
CAGR 3-Years
210%
|
CAGR 5-Years
121%
|
CAGR 10-Years
N/A
|
|
Merus NV
NASDAQ:MRUS
|
Revenue
$43.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Revenue
€97.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LAVA Therapeutics NV's Revenue?
Revenue
6.8m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Revenue amounts to 6.8m USD.
What is LAVA Therapeutics NV's Revenue growth rate?
Revenue CAGR 3Y
25%
Over the last year, the Revenue growth was -65%. The average annual Revenue growth rates for LAVA Therapeutics NV have been 25% over the past three years .